STipe Therapeutics

STipe Therapeutics Focuses on Harnessing the Innate Immune System to Combat Cancer. The company has developed first-in-class intracellular proteins targeting the STING pathway, a key driver of innate immunity and a modulator of tumorigenesis and autoimmune diseases. The company has identified and validated compounds that sensitize the STING pathway, thereby modulating the tumor microenvironment to support an effective anti-tumor response.